Table 6.
Results of phase II trials in esophageal cancer
| Author | Regimen | Histology | Therapy line | Response rate (%) | TTP/PFS | OS |
|---|---|---|---|---|---|---|
| Lee [20] | XP (X:2,500 mg/m2 D1-14 CDDP:60 mg/m2; D1) |
SCC (n = 45) |
1st line (n = 45) |
57.8% | 4.7 mon | 11.2 mon |
| Van Meerten [18] | XELOX (X:2,000 mg/m2 D1-14 O:130 mg/m2; D1) |
ADC (n = 45) SCC (n = 4) Undiff. (n = 2) |
1st line (n = 51) |
39% | NR | 8 mon |
| MB Polee [28] | Paclitaxel:180 mg/m2;D1 CDDP:60 mg/m2; D1 |
ADC (n = 31) SCC (n = 16) Undiff (n = 4) |
1st line (n = 51) |
ADC (39%) SCC (44%) |
NR | 9 mon |
| Zhang [29] | Paclitaxel:175 mg/m2 on D1 CDDP:75 mg/m2 (D1) |
SCC (n = 35) |
1st line (n = 35) |
48.6% | 7 mon | 13 mon |
| S.Lorenzen [21] | DX (X:2,000 mg/m2 D1-14 D:75 mg/m2; D1) |
ADC (n = 7) SCC (n = 17) |
1st (n = 16) 2nd (n = 8) |
1st (56%) 2nd (25%) Overall = 46% |
6.1 mon | 1st (15.8) 2nd (6.2) |
| S.Lorenzen [26] | FP + Cetuximab vs FP |
SCC (n = 62) | 1st line (n = 62) |
FP+ Cetuximab (19%) FP (13%) |
5.9 mon 3.6 mon |
9.5 mon 5.5 mon |
| Current Study | Xeloda 1,800 mg/m2 D1-14 Paclitaxel:80 mg/m2 on D1, D8 |
SCC (n = 32) | 1st (n = 12) 2nd (n = 20) |
1st (75%) 2nd (45%) Overall = 53.6% |
5.23 mon 4.54 mon |
14.3 mon 8.4 mon |
Abbreviations: XP, capecitabine/cisplatin; XELOX, capecitabine/oxaliplatin; DX, docetaxel/capecitabine; FP, 5-fluorouracil/cisplatin; SCC, squamous cell carcinoma; ADC, adenocarcinoma; Undiff, undifferentiated carcinoma; TTP, time to progression; PFS, progression-free survival; OS, overall survival; NR, not reported.